Symptoms and distress in children with advanced cancer: prospective patient-reported outcomes from the PediQUEST Study


Autoria(s): Wolfe, Joanne; Orellana, Liliana; Ullrich, Christina; Cook, E. Francis; Kang, Tammy I.; Rosenberg, Abby; Geyer, Russ; Feudtner, Chris; Dussel, Veronica
Data(s)

01/06/2015

Resumo

PURPOSE: Thousands of children are living with advanced cancer; yet patient-reported outcomes (PROs) have rarely been used to describe their experiences. We aimed to describe symptom distress in 104 children age 2 years or older with advanced cancer enrolled onto the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) Study (multisite clinical trial evaluating an electronic PRO system). <br /><br />METHODS: Symptom data were collected using age- and respondent-adapted versions of the PediQUEST Memorial Symptom Assessment Scale (PQ-MSAS) at most once per week. Clinical and treatment data were obtained from medical records. Individual symptom scores were dichotomized into high/low distress. Determinants of PQ-MSAS scores were explored using linear mixed-effects models. <br /><br />RESULTS: During 9 months of follow-up, PQ-MSAS was administered 920 times: 459 times in teens (99% self-report), 249 times in children ages 7 to 12 years (96% child/parent report), and 212 times in those ages 2 to 6 years (parent reports). Common symptoms included pain (48%), fatigue (46%), drowsiness (39%), and irritability (37%); most scores indicated high distress. Among the 73 PQ-MSAS surveys administered in the last 12 weeks of life, pain was highly prevalent (62%; 58% with high distress). Being female, having a brain tumor, experiencing recent disease progression, and receiving moderate- or high-intensity cancer-directed therapy in the prior 10 days were associated with worse PQ-MSAS scores. In the final 12 weeks of life, receiving mild cancer-directed therapy was associated with improved psychological PQ-MSAS scores. <br /><br />CONCLUSION: Children with advanced cancer experience high symptom distress. Strategies to promote intensive symptom management are indicated, especially with disease progression or administration of intensive treatments.

Identificador

http://hdl.handle.net/10536/DRO/DU:30072970

Publicador

American Society of Clinical Oncology

Relação

http://dro.deakin.edu.au/eserv/DU:30072970/orellana-symptomsand-2015.pdf

http://dro.deakin.edu.au/eserv/DU:30072970/orellana-symptomsand-inpress-2015.pdf

http://www.dx.doi.org/10.1200/JCO.2014.59.1222

Direitos

2015, American Society of Clinical Oncology

Tipo

Journal Article

Idioma(s)

eng

Palavras-Chave #Science & Technology #Life Sciences & Biomedicine #Oncology #QUALITY-OF-LIFE #PEDIATRIC PALLIATIVE CARE #CONTROLLED-TRIAL #THE-LITERATURE #PARENTS #END #ADOLESCENTS #NATIONWIDE #THERAPY